263 related articles for article (PubMed ID: 26772985)
1. Quality of life, clinical outcomes and safety of early prophylactic levothyroxine administration in patients with Graves' hyperthyroidism undergoing radioiodine therapy: a randomized controlled study.
Taïeb D; Bournaud C; Eberle MC; Catargi B; Schvartz C; Cavarec MB; Faugeron I; Toubert ME; Benisvy D; Archange C; Mundler O; Caron P; Abdullah AE; Baumstarck K
Eur J Endocrinol; 2016 Apr; 174(4):491-502. PubMed ID: 26772985
[TBL] [Abstract][Full Text] [Related]
2. Impaired Quality of Life After Radioiodine Therapy Compared to Antithyroid Drugs or Surgical Treatment for Graves' Hyperthyroidism: A Long-Term Follow-Up with the Thyroid-Related Patient-Reported Outcome Questionnaire and 36-Item Short Form Health Status Survey.
Törring O; Watt T; Sjölin G; Byström K; Abraham-Nordling M; Calissendorff J; Cramon PK; Filipsson Nyström H; Hallengren B; Holmberg M; Khamisi S; Lantz M; Wallin G
Thyroid; 2019 Mar; 29(3):322-331. PubMed ID: 30667296
[TBL] [Abstract][Full Text] [Related]
3. Changes in graves' ophthalmopathy after radioiodine and anti-thyroid drug treatment of Graves' disease from 2 prospective, randomized, open-label, blinded end point studies.
Chen DY; Schneider PF; Zhang XS; Luo XY; He ZM; Chen TH
Exp Clin Endocrinol Diabetes; 2014 Jan; 122(1):1-6. PubMed ID: 24203649
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up study of radioiodine treatment of hyperthyroidism.
Metso S; Jaatinen P; Huhtala H; Luukkaala T; Oksala H; Salmi J
Clin Endocrinol (Oxf); 2004 Nov; 61(5):641-8. PubMed ID: 15521969
[TBL] [Abstract][Full Text] [Related]
5. Cohort study on radioactive iodine-induced hypothyroidism: implications for Graves' ophthalmopathy and optimal timing for thyroid hormone assessment.
Stan MN; Durski JM; Brito JP; Bhagra S; Thapa P; Bahn RS
Thyroid; 2013 May; 23(5):620-5. PubMed ID: 23205939
[TBL] [Abstract][Full Text] [Related]
6. Quality-of-Life Impairments Persist Six Months After Treatment of Graves' Hyperthyroidism and Toxic Nodular Goiter: A Prospective Cohort Study.
Cramon P; Winther KH; Watt T; Bonnema SJ; Bjorner JB; Ekholm O; Groenvold M; Hegedüs L; Feldt-Rasmussen U; Rasmussen ÅK
Thyroid; 2016 Aug; 26(8):1010-8. PubMed ID: 27370744
[TBL] [Abstract][Full Text] [Related]
7. Thyroid-associated ophthalmopathy; quality of life follow-up of patients randomized to treatment with antithyroid drugs or radioiodine.
Abraham-Nordling M; Wallin G; Träisk F; Berg G; Calissendorff J; Hallengren B; Hedner P; Lantz M; Nyström E; Asman P; Lundell G; Törring O;
Eur J Endocrinol; 2010 Oct; 163(4):651-7. PubMed ID: 20660002
[TBL] [Abstract][Full Text] [Related]
8. Impact of lithium on efficacy of radioactive iodine therapy for Graves' disease: a cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal.
Bogazzi F; Giovannetti C; Fessehatsion R; Tanda ML; Campomori A; Compri E; Rossi G; Ceccarelli C; Vitti P; Pinchera A; Bartalena L; Martino E
J Clin Endocrinol Metab; 2010 Jan; 95(1):201-8. PubMed ID: 19906789
[TBL] [Abstract][Full Text] [Related]
9. Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment?
Tallstedt L; Lundell G; Blomgren H; Bring J
Eur J Endocrinol; 1994 May; 130(5):494-7. PubMed ID: 8180678
[TBL] [Abstract][Full Text] [Related]
10. [Radioiodine treatment of hyperthyroidism using a simplified dosimetric approach. Clinical results].
Giovanella L; De Palma D; Ceriani L; Vanoli P; Garancini S; Tordiglione M; Tarolo GL
Radiol Med; 2000 Dec; 100(6):480-3. PubMed ID: 11307510
[TBL] [Abstract][Full Text] [Related]
11. Post-radioiodine De Novo Onset Graves' Ophthalmopathy: Case Reports and a Review of the Literature.
Batra R; Krishnasamy SK; Buch H; Sandramouli S
Semin Ophthalmol; 2015 May; 30(3):227-31. PubMed ID: 24409943
[TBL] [Abstract][Full Text] [Related]
12. Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism.
Franklyn JA; Daykin J; Holder R; Sheppard MC
QJM; 1995 Mar; 88(3):175-80. PubMed ID: 7767667
[TBL] [Abstract][Full Text] [Related]
13. Outcomes in Relapsed Graves' Disease Patients Following Radioiodine or Prolonged Low Dose of Methimazole Treatment.
Villagelin D; Romaldini JH; Santos RB; Milkos AB; Ward LS
Thyroid; 2015 Dec; 25(12):1282-90. PubMed ID: 26414885
[TBL] [Abstract][Full Text] [Related]
14. Striving for euthyroidism in radioiodine therapy of Graves' disease: a 12-year prospective, randomized, open-label blinded end point study.
Chen DY; Schneider PF; Zhang XS; He ZM; Jing J; Chen TH
Thyroid; 2011 Jun; 21(6):647-54. PubMed ID: 21563916
[TBL] [Abstract][Full Text] [Related]
15. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy.
Bartalena L; Marcocci C; Bogazzi F; Manetti L; Tanda ML; Dell'Unto E; Bruno-Bossio G; Nardi M; Bartolomei MP; Lepri A; Rossi G; Martino E; Pinchera A
N Engl J Med; 1998 Jan; 338(2):73-8. PubMed ID: 9420337
[TBL] [Abstract][Full Text] [Related]
16. The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in Graves' hyperthyroidism: one-year follow-up of a prospective, randomized study.
Andrade VA; Gross JL; Maia AL
J Clin Endocrinol Metab; 2001 Aug; 86(8):3488-93. PubMed ID: 11502768
[TBL] [Abstract][Full Text] [Related]
17. A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active graves' ophthalmopathy.
Perros P; Kendall-Taylor P; Neoh C; Frewin S; Dickinson J
J Clin Endocrinol Metab; 2005 Sep; 90(9):5321-3. PubMed ID: 15985483
[TBL] [Abstract][Full Text] [Related]
18. Prevention of Orbitopathy by Oral or Intravenous Steroid Prophylaxis in Short Duration Graves' Disease Patients Undergoing Radioiodine Ablation: A Prospective Randomized Control Trial Study.
Vannucchi G; Covelli D; Campi I; Currò N; Dazzi D; Rodari M; Pepe G; Chiti A; Guastella C; Lazzaroni E; Salvi M
Thyroid; 2019 Dec; 29(12):1828-1833. PubMed ID: 31860407
[No Abstract] [Full Text] [Related]
19. Radioactive iodine therapy for pediatric Graves' disease: a single-center experience over a 10-year period.
Kaplowitz PB; Jiang J; Vaidyanathan P
J Pediatr Endocrinol Metab; 2020 Mar; 33(3):383-389. PubMed ID: 31603857
[TBL] [Abstract][Full Text] [Related]
20. A prospective randomized trial of antithyroid drug dose in Graves' disease therapy. European Multicenter Study Group on Antithyroid Drug Treatment.
Reinwein D; Benker G; Lazarus JH; Alexander WD
J Clin Endocrinol Metab; 1993 Jun; 76(6):1516-21. PubMed ID: 8501160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
